Cover Image
市場調查報告書

不寧腿症候群治療藥的全球市場:2015∼2019年

Global Restless Legs Syndrome Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 332644
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
不寧腿症候群治療藥的全球市場:2015∼2019年 Global Restless Legs Syndrome Market 2015-2019
出版日期: 2015年06月10日 內容資訊: 英文 80 Pages
簡介

不寧腿症候群(RLS)是神經疾病,由於伴隨四肢不快的疼痛,導致患者的睡眠障礙。男女中,全年齡皆可能發病,不過中年∼老年人為多。目前沒有特定的治療方法,以市場上的藥物緩和症狀。全球不寧腿症候群市場,預計2014∼2019年以年複合成長率11.46%擴大。

本報告提供全球不寧腿症候群治療藥市場相關詳細分析、市場趨勢與2015∼2019年的成長預測、產品概要與開發平台分析、各地區趨勢,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

第4章 調查方法

第5章 產品簡介

  • Mirapex/Sifrol/Mirapexin
  • Requip
  • Neupro/Leganto
  • HORIZANT/Regnite

第6章 簡介

第7章 疾病概要

  • RLS的理解
  • 病因
  • 症狀
  • 診斷
  • 管理
  • 流行病學
  • 經濟負擔

第8章 開發平台分析

  • 開發平台候補相關重要資訊

第9章 商業機會

第10章 領導品牌分析

第11章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第12章 各類藥物市場區隔

  • 多巴胺促效劑
  • 類鴉片物質
  • 抗痙攣劑
  • 鎮靜劑及安眠藥
  • 其他

第13章 各地區市場區隔

第14章 購買標準

第15章 市場成長的促進要素

第16章 促進要素與其影響

第17章 市場課題

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 供應商環境

  • 競爭模式
  • 市場佔有率調查:2014年
  • 其他未來預計處於的供應商

第22章 主要供應商調查

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort

第23章 本系列的其他報告

目錄
Product Code: IRTNTR6054

About RLS

RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.

Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.

Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Boehringer Ingelheim
  • GlaxoSmithKline
  • UCB
  • XenoPort

Other Prominent Vendors

  • Alexza Pharmaceuticals
  • Astellas Pharma
  • Axxonis Pharma
  • Bayer Healthcare
  • Impax Pharmaceuticals
  • Luitpold Pharmaceuticals
  • Merz Pharmaceuticals
  • Mundipharma
  • Newron Pharmaceuticals
  • Serina Therapeutics
  • Teva Neuroscience

Market driver

  • High unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Unknown disease etiology
  • For a full, detailed list, view our report

Market trend

  • Expected entry of drugs with multiple mechanisms and novel technologies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

  • 05.1. Mirapex/Sifrol/Mirapexin
  • 05.2. Requip
  • 05.3. Neupro/Leganto
  • 05.4. HORIZANT/Regnite

06. Introduction

07. Disease Overview

  • 07.1. Understanding RLS
    • 07.1.1. Types of RLS
  • 07.2. Etiology and Pathogenesis
    • 07.2.1. Genetic Factors
    • 07.2.2. Iron Deficiency
    • 07.2.3. Other Disease Conditions/Medications
    • 07.2.4. Neurological Disturbances
  • 07.3. Signs and Symptoms
  • 07.4. Diagnosis
    • 07.4.1. Differential Diagnosis of RLS
  • 07.5. Management
    • 07.5.1. Pharmacological Therapy
    • 07.5.2. Non-pharmacological Therapy
  • 07.6. Epidemiology
  • 07.7. Economic Burden

08. Pipeline Analysis

  • 08.1. Key Information on Pipeline Candidates
    • 08.1.1. Injectafer
    • 08.1.2. Lisuride
    • 08.1.3. Incobotulinumtoxin A
    • 08.1.4. IPX-159
    • 08.1.5. Safinamide
    • 08.1.6. AZ-008
    • 08.1.7. SER-214

09. Commercial Opportunities

10. Key Brand Analysis

11. Market Landscape

  • 11.1. Market Overview
  • 11.2. Market Size and Forecast
  • 11.3. Five Forces Analysis

12. Market Segmentation by Class of Drugs

  • 12.1. Dopaminergic Drugs
  • 12.2. Opioids
  • 12.3. Anticonvulsants
  • 12.4. Sedatives and Hypnotics
  • 12.5. Others

13. Geographical Segmentation

  • 13.1. Global Restless Legs Syndrome Market by Geography 2014-2019

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. UCB
    • 21.2.2. GlaxoSmithKline
    • 21.2.3. Boehringer Ingelheim
    • 21.2.4. XenoPort
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Boehringer Ingelheim
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Business Segmentation by Revenue 2013
    • 22.1.4. Business Segmentation by Revenue 2012 and 2013
    • 22.1.5. Geographical Segmentation by Revenue 2013
    • 22.1.6. Business Strategy
    • 22.1.7. Recent Developments
    • 22.1.8. SWOT Analysis
  • 22.2. GlaxoSmithKline
    • 22.2.1. Key facts
    • 22.2.2. Business overview
    • 22.2.3. Business segmentation by revenue 2014
    • 22.2.4. Business segmentation by revenue 2013 and 2014
    • 22.2.5. Geographical segmentation by revenue 2014
    • 22.2.6. Business strategy
    • 22.2.7. Recent developments
    • 22.2.8. SWOT analysis
  • 22.3. UCB
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Product Segmentation by Revenue 2013
    • 22.3.4. Product Segmentation by Revenue 2012 and 2013
    • 22.3.5. Geographical Segmentation by Revenue 2013
    • 22.3.6. Business Strategy
    • 22.3.7. Recent Developments
    • 22.3.8. SWOT Analysis
  • 22.4. XenoPort
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Strategy
    • 22.4.4. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of RLS
  • Exhibit 3: Prevalence of Primary and Secondary RLS 2014
  • Exhibit 4: Types of RLS based on Onset of Disease
  • Exhibit 5: Etiology of RLS
  • Exhibit 6: Symptoms of RLS
  • Exhibit 7: Differential Diagnosis of RLS
  • Exhibit 8: Treatment Options for RLS
  • Exhibit 9: Prevalence of RLS Based on Gender
  • Exhibit 10: Pipeline Portfolio of Global Restless Legs Syndrome Market
  • Exhibit 11: Commercial Opportunities for Global Restless Legs Syndrome Market
  • Exhibit 12: Global Restless Legs Syndrome Market 2014-2019 ($ millions)
  • Exhibit 13: Global Restless Legs Syndrome Market by Class of Drugs
  • Exhibit 14: Global Restless Legs Syndrome Market by Geography 2014
  • Exhibit 15: Vendor Ranking 2014
  • Exhibit 16: Neupro: YoY Growth Rate and Revenue 2010-2014 ($ millions)
  • Exhibit 17: Neupro: Region-wise Revenue Comparison 2012-2014 ($ millions)
  • Exhibit 18: Requip: YoY Growth Rate and Revenue 2010-2014 ($ millions)
  • Exhibit 19: Region-wise Revenue Comparison of Requip 2012-2014 ($ millions)
  • Exhibit 20: HORIZANT: US Revenue 2013-2014 ($ millions)
  • Exhibit 21: Regnite: Revenue in Japan 2013-2014 ($ millions)
  • Exhibit 22: Boehringer Ingelheim: Business Segmentation by Revenue 2013
  • Exhibit 23: Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 24: Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
  • Exhibit 25: GlaxoSmithKline: Business segmentation by revenue 2014
  • Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 27: GlaxoSmithKline: Geographical segmentation by revenue 2014
  • Exhibit 28: UCB: Product Segmentation by Revenue 2013
  • Exhibit 29: UCB: Product Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 30: UCB: Geographical Segmentation by Revenue 2013
Back to Top